Highlights
- Strategic Acquisition: Little Green Pharma signs a binding letter of intent to acquire Health House Australia Pty Ltd for $1.25 million.
- Revenue Boost: Health House, a cashflow breakeven business, generates $7.5 million in annual revenue.
- Market Reaction: LGP shares rose 4%, trading at 13 cents on December 20, 2024.
Little Green Pharma Ltd (ASX:LGP) has announced its intention to acquire Health House Australia Pty Ltd for $1.25 million, in a move aimed at enhancing vertical integration and capitalizing on operational synergies within the medicinal cannabis market. The acquisition aligns with LGP's strategy of leveraging current market conditions to acquire sustainable businesses at attractive valuations.
Health House, a distributor in the medicinal cannabis space, operates at cashflow breakeven and generates approximately $7.5 million in annual revenue. Post-acquisition, Health House is expected to continue serving as a key distribution partner for LGP while also integrating into the company’s broader operations.
Details of the Transaction
Under the binding letter of intent (LOI), LGP has secured exclusivity until January 31, 2025, to conduct due diligence and finalize terms for acquiring 100% of Health House's issued shares. The acquisition terms include:
- A purchase price of $1.25 million, calculated on a cash-free, debt-free basis as of January 31, 2025.
- Adjustments for net payables and receivables at closing.
- A non-refundable deposit of $50,000 and a refundable deposit of $25,000, both of which will be applied to the final purchase price upon closing.
- The option for LGP to complete the acquisition during the exclusivity period.
Strategic Rationale
The acquisition is expected to deliver significant operational synergies for LGP, enhancing its vertical integration capabilities while expanding its revenue base. Health House's existing distribution network will remain a critical component of LGP's operations, ensuring continuity and growth potential.
LGP highlighted that the transaction offers an attractive valuation, further reinforcing its strategic focus on acquiring cashflow-positive or breakeven medicinal cannabis businesses.
Market Reaction and Outlook
Following the announcement, shares of LGP rose 4%, reaching 13 cents as of December 20, 2024. The modest market reaction reflects investor optimism about the acquisition's potential to strengthen LGP's position in the medicinal cannabis industry.